Rheumatic diseases are chronic diseases involving the inflammation and severe pain in joints, tendons, ligaments, bones, and muscles. Examples of rheumatic diseases include Osteoarthritis, Rheumatoid arthritis, Fibromyalgia, Gout, Psoriatic arthritis, Scleroderma, etc. Complications induced by rheumatic diseases can lead to lower articular function and higher mortality. In addition, these can affect the ability of the patients to work properly, and also affect their social relationships. Hence, medical researchers have devoted their time and efforts to develop effective drugs for the treatment of these diseases.
Clinical research has identified that people with the age between 40 and 50 suffer mostly from rheumatic diseases. However, elderly patients and children may also suffer from these conditions. Different factors, like drug use, infection due to human immunodeficiency virus and streptococcus, and excessive stress on a joint due to injury, and different genes and hormones work as the contributing factor for these severe diseases.
According to a study, around 30 percent of people of the world suffer from rheumatic diseases. More than 46 million Americans suffer from these diseases. The standardized mortality ratios vary from 1.28 to 2.98. In recent times, the cases of rheumatic diseases have increased in a significant manner.
Market of Anti-Rheumatics
In 2016, global anti-rheumatic drugs sale reached $53.3 billion. Abbvie, a global pharmaceutical company, still dominates the anti-rheumatic market, with the market share of 30.2%. Celgene is also maintaining its leading position due to the immense popularity of Otezla, which exceeded $1 billion in sales in 2016.
The best-selling anti-rheumatic product is Humira from Abbvie, with $16.5 billion in sales in 2016. Amgen’s Amjevita has also put up a tough competition in ant-rheumatic drugs market.